Seeking Alpha
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

Vivus: Qsymia Sales Dip - Is A Lower Price Needed?

Vivus (VVUS) investors have seen Qsymia scripts remain in a pretty tight channel for over 15 months. While the sales have remained fairly steady, the arrival of a new competitor could have shifted the market in such a way that Vivus will have little choice but to respond. Further, yet another competitor in Novo Nordisk (NVO) with Saxenda may enter the space in the next few months.

This week sales of the anti-obesity drug Qsymia were about 10,200 according to industry tracker IMS Health. That level of sales was 3.5% lower than what we saw last week. In essence, the flat sales we have seen for many months are now in decline.

Chart Source - Spencer Osborne

Up until October of 2014 Qsymia was the least expensive new anti-obesity drug on the market. Even with a pricing advantage, Vivus could not really find a solution to drive script growth. The… Read More …